Immunocore (IMCR)
28.50
-1.53 (-5.09%)
At close: Jan 14, 2025, 3:59 PM
27.00
-5.26%
After-hours Jan 14, 2025, 04:23 PM EST
undefined% (undefined)
| Bid | 11.49 |
| Market Cap | 1.43B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.95 |
| PE Ratio (ttm) | -30 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 36.61 |
| Volume | 301,729 |
| Avg. Volume (20D) | 269,993 |
| Open | 30.20 |
| Previous Close | 30.03 |
| Day's Range | 28.50 - 30.24 |
| 52-Week Range | 27.69 - 76.98 |
| Beta | undefined |
About IMCR
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (N...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 497
Stock Exchange NASDAQ
Ticker Symbol IMCR
Website https://www.immunocore.com
Analyst Forecast
According to 12 analyst ratings, the average rating for IMCR stock is "Buy." The 12-month stock price forecast is $66.5, which is an increase of 133.33% from the latest price.
Buy 58.33%
Hold 33.33%
Sell 8.33%
Next Earnings Release
Immunocore is scheduled to release its earnings on Feb 26, 2025,
before market opens.
Analysts project revenue of $83.72M, reflecting a 19.32% YoY growth and earnings per share of -0.4, making a 0.00% YoY.
Analysts project revenue of $83.72M, reflecting a 19.32% YoY growth and earnings per share of -0.4, making a 0.00% YoY.
